Half-year report · Q2

Period2024-06-01 → 2024-11-30
Filed2025-01-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥31.4bn2024-06-01 → 2024-11-30Cons.Net sales
Revenue¥61.6bn2023-06-01 → 2024-05-31Cons.Net sales (5-year summary)
Revenue¥28.9bn2023-06-01 → 2023-11-30Cons.Net sales
Operating income¥522m2024-06-01 → 2024-11-30Cons.Operating income
Operating income¥618m2023-06-01 → 2023-11-30Cons.Operating income
Ordinary income¥552m2024-06-01 → 2024-11-30Cons.Ordinary income
Ordinary income¥1.0bn2023-06-01 → 2024-05-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥645m2023-06-01 → 2023-11-30Cons.Ordinary income
Profit before tax¥586m2024-06-01 → 2024-11-30Cons.Income before income taxes
Profit before tax¥700m2023-06-01 → 2023-11-30Cons.Income before income taxes
Net income (owners)¥338m2024-06-01 → 2024-11-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥580m2023-06-01 → 2024-05-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥480m2023-06-01 → 2023-11-30Cons.Profit loss attributable to owners of parent
Net income¥337m2024-06-01 → 2024-11-30Cons.Profit loss
Net income¥477m2023-06-01 → 2023-11-30Cons.Profit loss
Total assets¥26.4bnat 2024-11-30Cons.Assets
Total assets¥26.6bnat 2024-05-31Cons.Assets
Total assets¥24.8bnat 2023-11-30Cons.Total assets (5-year summary)
Total liabilities¥17.7bnat 2024-11-30Cons.Liabilities
Total liabilities¥18.0bnat 2024-05-31Cons.Liabilities
Net assets / equity¥8.7bnat 2024-11-30Cons.Net assets
Net assets / equity¥8.6bnat 2024-05-31Cons.Net assets
Net assets / equity¥8.3bnat 2023-11-30Cons.Net assets (5-year summary)
Cash and deposits¥4.4bnat 2024-11-30Cons.Cash and deposits
Cash and deposits¥5.3bnat 2024-05-31Cons.Cash and deposits
Cash & equivalents¥4.4bnat 2024-11-30Cons.Cash and cash equivalents
Cash & equivalents¥5.3bnat 2024-05-31Cons.Cash and cash equivalents
Cash & equivalents¥5.0bnat 2023-11-30Cons.Cash and cash equivalents
Cash & equivalents¥5.8bnat 2023-05-31dCons.Cash and cash equivalents
Operating cash flow−¥633m2024-06-01 → 2024-11-30Cons.Net cash provided by used in operating activities
Operating cash flow¥878m2023-06-01 → 2024-05-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥544m2023-06-01 → 2023-11-30Cons.Net cash provided by used in operating activities
Investing cash flow¥19m2024-06-01 → 2024-11-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥1.1bn2023-06-01 → 2024-05-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥154m2023-06-01 → 2023-11-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥239m2024-06-01 → 2024-11-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥335m2023-06-01 → 2024-05-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥123m2023-06-01 → 2023-11-30Cons.Net cash provided by used in financing activities
EPS (basic)¥136.82024-06-01 → 2024-11-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥227.962023-06-01 → 2024-05-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥188.052023-06-01 → 2023-11-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio32.9%at 2024-11-30Cons.Equity to asset ratio (5-year summary)
Equity ratio32.2%at 2024-05-31Cons.Equity to asset ratio (5-year summary)
Equity ratio33.5%at 2023-11-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-06-01 → 2024-11-30¥0
Reconciling Itemsreconcilingrevenue intersegment2024-06-01 → 2024-11-30¥0
Reconciling Itemsreconcilingsegment profit2024-06-01 → 2024-11-30−¥519m
jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segmentrevenue2024-06-01 → 2024-11-30¥113m
jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segmentrevenue external2024-06-01 → 2024-11-30¥112m
jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segmentrevenue intersegment2024-06-01 → 2024-11-30¥0
jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segmentsegment profit2024-06-01 → 2024-11-30−¥82m
jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segmentrevenue2024-06-01 → 2024-11-30¥31.2bn
jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segmentrevenue external2024-06-01 → 2024-11-30¥31.2bn
jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segmentrevenue intersegment2024-06-01 → 2024-11-30¥0
jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segmentsegment profit2024-06-01 → 2024-11-30¥1.1bn
jpcrp040300-q2r_E33393-000Medical Mallreportable segmentrevenue2024-06-01 → 2024-11-30¥35m
jpcrp040300-q2r_E33393-000Medical Mallreportable segmentrevenue external2024-06-01 → 2024-11-30¥35m
jpcrp040300-q2r_E33393-000Medical Mallreportable segmentsegment profit2024-06-01 → 2024-11-30¥0
—segment totalrevenue2024-06-01 → 2024-11-30¥31.4bn
—segment totalrevenue external2024-06-01 → 2024-11-30¥31.4bn
—segment totalrevenue intersegment2024-06-01 → 2024-11-30¥0
—segment totalsegment profit2024-06-01 → 2024-11-30¥1.0bn
Reconciling Itemsreconcilingrevenue2023-06-01 → 2023-11-30¥0
Reconciling Itemsreconcilingrevenue intersegment2023-06-01 → 2023-11-30¥0
Reconciling Itemsreconcilingsegment profit2023-06-01 → 2023-11-30−¥494m
jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segmentrevenue2023-06-01 → 2023-11-30¥146m
jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segmentrevenue external2023-06-01 → 2023-11-30¥146m
jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segmentrevenue intersegment2023-06-01 → 2023-11-30¥0
jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segmentsegment profit2023-06-01 → 2023-11-30¥6m
jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segmentrevenue2023-06-01 → 2023-11-30¥28.7bn
jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segmentrevenue external2023-06-01 → 2023-11-30¥28.7bn
jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segmentrevenue intersegment2023-06-01 → 2023-11-30¥0
jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segmentsegment profit2023-06-01 → 2023-11-30¥1.1bn
jpcrp040300-q2r_E33393-000Medical Mallreportable segmentrevenue2023-06-01 → 2023-11-30¥36m
jpcrp040300-q2r_E33393-000Medical Mallreportable segmentrevenue external2023-06-01 → 2023-11-30¥36m
jpcrp040300-q2r_E33393-000Medical Mallreportable segmentsegment profit2023-06-01 → 2023-11-30¥2m
—segment totalrevenue2023-06-01 → 2023-11-30¥28.9bn
—segment totalrevenue external2023-06-01 → 2023-11-30¥28.9bn
—segment totalrevenue intersegment2023-06-01 → 2023-11-30¥0
—segment totalsegment profit2023-06-01 → 2023-11-30¥1.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 485
ItemContextValueUnit
Independent auditors report consolidated (text)FilingDateInstantText · Plus
Audit firm1 consolidatedFilingDateInstant
Original text (Japanese)有限責任監査法人トーマツ
Cpa1 audit firm1 consolidatedFilingDateInstant
Original text (Japanese) 上 田 知 範
Cpa2 audit firm1 consolidatedFilingDateInstant
Original text (Japanese) 髙 尾 圭 輔
Number of submissionFilingDateInstant1
Net sales (5-year summary)Prior1YTDDuration28899000000JPY
Net sales (5-year summary)CurrentYTDDuration31362000000JPY
Net sales (5-year summary)Prior1YearDuration61555000000JPY
Ordinary income loss (5-year summary)Prior1YTDDuration645000000JPY
Ordinary income loss (5-year summary)CurrentYTDDuration552000000JPY
Ordinary income loss (5-year summary)Prior1YearDuration1020000000JPY
Profit loss attributable to owners of parent (5-year summary)Prior1YTDDuration480000000JPY
Profit loss attributable to owners of parent (5-year summary)CurrentYTDDuration338000000JPY
Profit loss attributable to owners of parent (5-year summary)Prior1YearDuration580000000JPY
Comprehensive income (5-year summary)Prior1YTDDuration539000000JPY
Comprehensive income (5-year summary)CurrentYTDDuration392000000JPY
Comprehensive income (5-year summary)Prior1YearDuration920000000JPY
Net assets (5-year summary)Prior1QuarterInstant8341000000JPY
Net assets (5-year summary)CurrentQuarterInstant8709000000JPY
Net assets (5-year summary)Prior1YearInstant8556000000JPY
Total assets (5-year summary)Prior1QuarterInstant24827000000JPY
Total assets (5-year summary)CurrentQuarterInstant26442000000JPY
Total assets (5-year summary)Prior1YearInstant26557000000JPY
Basic earnings loss per share (5-year summary)Prior1YTDDuration188.05
Basic earnings loss per share (5-year summary)CurrentYTDDuration136.80
Basic earnings loss per share (5-year summary)Prior1YearDuration227.96
Diluted earnings per share (5-year summary)Prior1YTDDuration-
Diluted earnings per share (5-year summary)CurrentYTDDuration-
Diluted earnings per share (5-year summary)Prior1YearDuration-
Equity to asset ratio (5-year summary)Prior1QuarterInstant0.335
Equity to asset ratio (5-year summary)CurrentQuarterInstant0.329
Equity to asset ratio (5-year summary)Prior1YearInstant0.322
Net cash provided by used in operating activities (5-year summary)Prior1YTDDuration-544000000JPY
Net cash provided by used in operating activities (5-year summary)CurrentYTDDuration-633000000JPY
Net cash provided by used in operating activities (5-year summary)Prior1YearDuration878000000JPY
Net cash provided by used in investing activities (5-year summary)Prior1YTDDuration-154000000JPY
Net cash provided by used in investing activities (5-year summary)CurrentYTDDuration19000000JPY
Net cash provided by used in investing activities (5-year summary)Prior1YearDuration-1067000000JPY
Net cash provided by used in financing activities (5-year summary)Prior1YTDDuration-123000000JPY
Net cash provided by used in financing activities (5-year summary)CurrentYTDDuration-239000000JPY
Net cash provided by used in financing activities (5-year summary)Prior1YearDuration-335000000JPY
Cash and cash equivalents (5-year summary)Prior1QuarterInstant5002000000JPY
Cash and cash equivalents (5-year summary)CurrentQuarterInstant4447000000JPY
Cash and cash equivalents (5-year summary)Prior1YearInstant5300000000JPY
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember2553000
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember2553000
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant2553000
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant2553000
Number of shares heldCurrentQuarterInstant_No1MajorShareholdersMember348400
Shareholding ratioCurrentQuarterInstant_No1MajorShareholdersMember0.1413

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-05-31pass rounding
balance sheet identityconsolidated 2024-11-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-05-31pass
statement vs summary · net assetsconsolidated 2024-11-30pass
statement vs summary · net income attributable to parentconsolidated 2023-06-01/2023-11-30pass
statement vs summary · net income attributable to parentconsolidated 2024-06-01/2024-11-30pass
statement vs summary · operating cash flowconsolidated 2023-06-01/2023-11-30pass
statement vs summary · operating cash flowconsolidated 2024-06-01/2024-11-30pass
statement vs summary · revenueconsolidated 2023-06-01/2023-11-30pass
statement vs summary · revenueconsolidated 2024-06-01/2024-11-30pass
statement vs summary · total assetsconsolidated 2024-05-31pass
statement vs summary · total assetsconsolidated 2024-11-30pass